• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Fragile X Syndrome Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome.
  • The report assesses Fragile X Syndrome pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Fragile X Syndrome pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Fragile X Syndrome ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Neuren Pharmaceuticals, Addex Pharmaceuticals, Seaside Therapeutics, Ecopia BioSciences, NexGenix Pharmaceuticals, Neuropharm, Merck & Co, Afraxis, Sage Therapeutics, Kareus Therapeutics, Zynerba Pharmaceuticals, Selvita, Hua Medicine, Confluence Pharmaceuticals, Fulcrum Therapeutics, Vencerx Therapeutics, Purdue Pharma, Cortex Pharmaceuticals, XenoPort, Roche, Alcobra, Neurotrope BioScience

Key Drugs:

Trofinetide, Diazepinomicin, Fenobam, STX 107, KU 046, ZYN 002, AMO 01, Acamprosate, Ganaxolone, Memantine, Gaboxadol, Basimglurant, Arbaclofen, Metadoxine extended-release, Bryostatin, Mavoglurant, ANAVEX 2-73

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8
Price:

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry





Leave a Reply

Your email address will not be published.

Contact
+91 9643310025, 9643312749
© 2019 Pharmintel